Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Parexel International, a US-based provider of biopharmaceutical services, has opened offices in Chengdu and Guangzhou to support a growing requirement for a range of clinical development and regulatory consulting capabilities in China and throughout the Asia/Pacific region.
Subscribe to our email newsletter
The locations further expand Parexel’s presence in China, which includes offices in Beijing and Shanghai as well as Kowloon, Hong Kong. Parexel now has 17 biopharmaceutical centres in the Asia/Pacific region, which in addition to China also includes the presence in Australia, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand.
Josef von Rickenbach, chairman and CEO of Parexel International, said: “Foreseeing China’s potential for clients, Parexel was a pioneer in establishing a firm foundation for clinical development in the country. Further expansion of expert resources in Asia is designed to meet client demand for greater opportunities to include China in their global drug development strategies and obtain China market registration.
“We believe that China is attractive for a wide range of clinical development activities due to its large patient population, cost effective environment, and expanding medical infrastructure. We are working with clients to reduce their development costs, accelerate patient recruitment, and decrease time to market by incorporating China in global development planning, thereby bringing important new safe and effective treatments to patients in China and around the world sooner.”